Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996425 | 1.00 | MAP3K14 (0.39) | MAP3K14MAPT | |
| Hydrochloric Acid SCHEMBL15546671 | 0.98 | MAP3K14 (0.38) | MAP3K14MAPT | |
| SCHEMBL4591427 | 0.90 | MAPT (0.38) | MAP3K14MAPT | |
| SCHEMBL3489916 | 0.67 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL14119779 | 0.64 | — | — | |
| SCHEMBL346877 | 0.64 | — | — | |
| SCHEMBL7443364 | 0.62 | — | — | |
| SCHEMBL10470252 | 0.59 | — | — | |
| SCHEMBL748562 | 0.54 | — | — | |
| SCHEMBL7640738 | 0.54 | MAPT (0.65) | MAP3K14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057966-B1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS SPA (IT) | 2017-07-26 | — | — | EP | claimed |
| US-9518047-B2 | Process for the industrial synthesis of lurasidone | PROCOS S.P.A. (IT) | 2016-12-13 | — | — | US | claimed |
| EP-3057966-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | Procos S.p.A. (IT) | 2016-08-24 | — | — | EP | claimed |
| US-20160237077-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2016-08-18 | — | — | US | claimed |
| WO-2015056205-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2015-04-23 | — | — | WO | claimed |
| EP-3057966-B1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS SPA (IT) | 2017-07-26 | — | — | EP | disclosed |
| US-9518047-B2 | Process for the industrial synthesis of lurasidone | PROCOS S.P.A. (IT) | 2016-12-13 | — | — | US | disclosed |
| EP-2563790-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3057966-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | Procos S.p.A. (IT) | 2016-08-24 | — | — | EP | disclosed |
| US-20160237077-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| WO-2015056205-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2015-04-23 | — | — | WO | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2563791-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | MAP3K14 2513/4885MAPT 2417/4885 |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | MAP3K14 2752/4885MAPT 2969/4885 |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | MAP3K14 2513/4885MAPT 2417/4885 |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | MAP3K14 2752/4885MAPT 2969/4885 |
| US-20160237077-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | REN, DCXR, ADRA1D | MAP3K14 2042/4885MAPT 1466/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | MAP3K14 2431/4885MAPT 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.